Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs
Retrieved on:
Tuesday, March 3, 2020
2019 was a year in which we laid the foundations for a new era for Chi-Med, said Simon To, Chairman of Chi-Med.
Key Points:
- 2019 was a year in which we laid the foundations for a new era for Chi-Med, said Simon To, Chairman of Chi-Med.
- Set out below are some of Chi-Meds operating highlights for 2019 and so far this year.
- As a result of our regulatory interaction with the NMPA12, we now expect to submit savolitinib NDA in early 2020.
- Promising savolitinib efficacy in MET-amplified gastric cancer: The VIKTORY Phase II umbrella trial results were published in Cancer Discovery16.